Acute toxicity of hypofractionated intensitymodulated radiotherapy for prostate cancer

Current Oncology

Volumn 22, Issue 2, 2015, Pages e76-e84

  Drodge, C S ^a,b   Boychak, O ^a   Patel, S ^a   Usmani, N ^a   Amanie, J ^a   Parliament, M B ^a   Murtha, A ^a   Field, C ^a   Ghosh, S ^a   Pervez, Nadeem ^a  

^a CROSS CANCER INSTITUTE   (Canada)

^b Eastern Health Canada   (Canada)

Author keywords

Acute toxicity; Androgen suppression; High risk prostate cancer; Hypofractionated radiotherapy; Intensity modulated radiotherapy

Indexed keywords

ACUTE TOXICITY; ADULT; AGED; ARTICLE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; HYPOFRACTIONATED INTENSITY MODULATED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; MALE; PROSPECTIVE STUDY; PROSTATE CANCER; PUBLIC HEALTH; RISK FACTOR; TREATMENT OUTCOME; TREATMENT PLANNING; UROGENITAL TRACT DISEASE;

EID: 84928242210     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.22.2247     Document Type: Article

References (36)

1. Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2014. Toronto, ON: Canadian Cancer Society; 2014. [Available online at: http://www.cancer.ca/~/media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/Canadian-Cancer-Statistics-2014-EN.pdf; cited October 30, 2014]
2. American Cancer Society (acs). Cancer Facts and Figures 2014. Atlanta, GA: acs; 2014. [Available online at: http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf; cited October 30, 2014]
3. Peeters ST, Heemsbergen WD, Koper PC, et al. Dose–response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase iii trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006;24:1990–6.
4. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase iii randomized trial. Int J Radiat Oncol Biol Phys 2002;53:1097–105.
5. Fowler JF, Ritter MA, Chappell RJ, Brenner DJ. What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys 2003;56:1093–104.
6. Arcangeli S, Strigari L, Gomellini S, et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012;84:1172–8.
7. Lukka H, Hayter C, Julian JA, et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 2005;23:6132–8.
8. Pollack A, Hanlon AL, Horwitz EM, et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 2006;64:518–26.
9. Yeoh EE, Holloway RH, Fraser RJ, et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase iii randomized trial. Int J Radiat Oncol Biol Phys 2006;66:1072–83.
10. Pervez N, Small C, MacKenzie M, et al. Acute toxicity in highrisk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2010;76:57–64.
11. Kitamura K, Shirato H, Shinohara N, et al. Reduction in acute morbidity using hypofractionated intensity-modulated radiation therapy assisted with a fluoroscopic real-time tumortracking system for prostate cancer: preliminary results of a phase i/ii study. Cancer J 2003;9:268–76.
12. Kupelian PA, Thakkar VV, Khuntia D, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys 2005;63:1463–8.
13. Soete G, Arcangeli S, De Meerleer G, et al. Phase ii study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: report on acute toxicity. Radiother Oncol 2006;80:78–81.
14. Junius S, Haustermans K, Bussels B, et al. Hypofractionated intensity modulated irradiation for localized prostate cancer, results from a phase i/ii feasibility study. Radiat Oncol 2007;2:29.
15. Martin JM, Rosewall T, Bayley A, et al. Phase ii trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 2007;69:1084–9.
16. Leborgne F, Fowler J. Acute toxicity after hypofractionated conformal radiotherapy for localized prostate cancer: nonrandomized contemporary comparison with standard fractionation. Int J Radiat Oncol Biol Phys 2008;72:770–6.
17. McCammon R, Rusthoven KE, Kavanagh B, Newell S, Newman F, Raben D. Toxicity assessment of pelvic intensitymodulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2009;75:413–20.
18. Macias V, Gonzalez Celador R, Marti-Macia C, Cigarral C, Perez-Romasanta LA. Prognostic factors for acute toxicity in prostate cancer patients treated with high-dose hypofractionated radiotherapy. Clin Transl Oncol 2013;15:643–51.
19. Arcangeli G, Saracino B, Gomellini S, et al. A prospective phase iii randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2010;78:11–18.
20. Dearnaley D, Syndikus I, Sumo G, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the chhip randomised controlled trial. Lancet Oncol 2012;13:43–54.
21. Jereczek-Fossa BA, Zerini D, Fodor C, et al. Acute toxicity of image-guided hypofractionated radiotherapy for prostate cancer: nonrandomized comparison with conventional fractionation. Urol Oncol 2011;29:523–32.
22. Lock M, Best L, Wong E, et al. A phase ii trial of arc-based hypofractionated intensity-modulated radiotherapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 2011;80:1306–15.
23. Pollack A, Walker G, Buyyounouski M, et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer [abstract]. Int J Radiat Oncol Biol Phys 2011;81(suppl):S1.
24. Quon HC, Cheung P, Chu W, et al. Phase i/ii study of extreme hypofractionation for localized prostate cancer: acute toxicity and quality of life [abstract 2403]. Int J Radiat Oncol Biol Phys 2011;81(suppl):S404.
25. Quon H, Cheung PC, Loblaw DA, et al. Hypofractionated concomitant intensity-modulated radiotherapy boost for highrisk prostate cancer: late toxicity. Int J Radiat Oncol Biol Phys 2012;82:898–905.
26. Valeriani M, Monaco F, Osti MF, De Sanctis V, Minniti G, Enrici RM. Hypofractionated radiotherapy with or without igrt in prostate cancer: preliminary report of acute toxicity. Anticancer Res 2011;31:3555–8.
27. Yeoh EE, Botten RJ, Butters J, Di Matteo AC, Holloway RH, Fowler J. Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase iii randomized trial. Int J Radiat Oncol Biol Phys 2011;81:1271–8.
28. Adkison JB, McHaffie DR, Bentzen SM, et al. Phase i trial of pelvic nodal dose escalation with hypofractionated imrt for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012;82:184–90.
29. Aluwini S, Pos F, van Lin E, et al. Acute toxicity of the randomized phase iii Dutch hypofractionation trial (hypro) for prostate cancer [abstract OC-0218]. Radiother Oncol 2012;103(suppl 1):S84–5.
30. Drodge S, Boychak A, Patel S, et al. Phase 2 study: feasibility and acute toxicity of dose-escalated hypofractionated intensity modulated radiation therapy with concurrent treatment of pelvic lymph nodes in high-risk prostate cancer patients [abstract]. Int J Radiat Oncol Biol Phys 2013;87(suppl):S364.
31. Lukka H. Prostate cancer: risk categories and role of hormones and radiotherapy. Can J Urol 2002;9(suppl 1):26–9.
32. Arcangeli G, Fowler J, Gomellini S, et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011;79:1013–21.
33. Shirato H, Shimizu S, Kunieda T, et al. Physical aspects of a real-time tumor-tracking system for gated radiotherapy. Int J Radiat Oncol Biol Phys 2000;48:1187–95.
34. Aluwini S, Pos F, Schimmel E, et al. Late toxicity in the randomized phase iii Dutch Hypofractionation Trial for prostate cancer patients (hypro) [abstract OC-0052]. Radiother Oncol 2013;106(suppl 2):S19.
35. Yuen J, Rodrigues G, Trenka K, et al. Comparing two strategies of dynamic intensity modulated radiation therapy (dimrt) with 3-dimensional conformal radiation therapy (3dcrt) in the hypofractionated treatment of high-risk prostate cancer. Radiat Oncol 2008;3:1.
36. Rana S, Cheng CY, Zheng Y, et al. Proton therapy vs. vmat for prostate cancer: a treatment planning study. Int J Part Ther 2014;1:22–3.